Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coya Therapeutics (COYA) Income from Continuing Operations (2022 - 2025)

Coya Therapeutics' Income from Continuing Operations history spans 4 years, with the latest figure at 2432897.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 45.33% year-over-year to 2432897.0; the TTM value through Sep 2025 reached 19914926.0, down 88.25%, while the annual FY2024 figure was 14882492.0, 86.31% down from the prior year.
  • Income from Continuing Operations for Q3 2025 was 2432897.0 at Coya Therapeutics, up from 6094977.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1815155.0 in Q4 2023 and bottomed at 7306757.0 in Q1 2025.
  • The 4-year median for Income from Continuing Operations is 3254345.0 (2023), against an average of 3334939.73.
  • The largest annual shift saw Income from Continuing Operations soared 190.6% in 2023 before it crashed 324.79% in 2024.
  • A 4-year view of Income from Continuing Operations shows it stood at 2003518.0 in 2022, then skyrocketed by 190.6% to 1815155.0 in 2023, then plummeted by 324.79% to 4080295.0 in 2024, then skyrocketed by 40.37% to 2432897.0 in 2025.
  • Per Business Quant, the three most recent readings for COYA's Income from Continuing Operations are 2432897.0 (Q3 2025), 6094977.0 (Q2 2025), and 7306757.0 (Q1 2025).